Skip to content
Simpler Grants

No. HT942526BCRPBTA4 · Defense Health Agency Contracting Activity - DHACA

Open

DoW Breast Cancer, Breakthrough Award Level 4

grants.gov listing Full announcement (NOFO)
Dealbreakers No cost share required Audit: not stated Reimbursement-only: not stated
Invitation only
“Invitation to Submit an Application: July 16, 2026” — From the announcement

At a glance

AI summary

This program funds large-scale breast cancer research with clinical trials, including comparative effectiveness trials, that could transform prevention or treatment. Applicants must include two or more breast cancer consumer advocates, and the program also allows either one principal investigator or two partnering principal investigators. The award is expected to fund about one application, with a total cost cap of $21 million and a maximum project period of four years. Cost sharing is not required. Eligible applicants include U.S. Department of War organizations and domestic or foreign public or private, for-profit or nonprofit organizations; the research must be relevant to Service Members, Veterans, their Families, and/or the American public.

AI-generated summary — verify against the announcement

What it funds

  • Science and Technology and other Research and Development
  • Research & Discovery
  • Patients & People with Health Conditions
  • Researchers & Scholars
  • Biomedical & Disease Research
Official description from grants.gov

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 4. Distinctive Features: · Clinical trials are required. · The research team must include two or more breast cancer consumer advocates. · This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.

Who can apply

  • Unrestricted
Geographic restriction None found in the announcement — likely nationwide